Pollinex Quattro Tree: allergy vaccine

Gawchik, Sandra M.; Saccar, Consuelo L.

doi:10.1517/14712590802699596

Cited by 23 publications

(16 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The usual target maintenance dose is between 5 and 20 mg purified major allergen [42] but the maintenance dose and interval may also need to be modified as some patients only tolerate smaller doses. Pre-seasonal immunotherapy is an alternative approach that involves administration of four to seven incremental dosages at weekly intervals, before the start of the specific pollen season for three consecutive years [31,121]. In patients receiving immunotherapy to both tree and grass pollens, injections should be given separately with a minimum interval of 30 min between injections.…”

Section: Dosing Schedules For Subcutaneous Immunotherapymentioning

confidence: 99%

Immunotherapy for allergic rhinitis

Walker¹,

Durham

Till

et al. 2011

Clin Experimental Allergy

146

125

View full text Add to dashboard Cite

SummaryAllergic rhinitis (AR) affects more than 20% of the population in the United Kingdom and western Europe and represents a major cause of morbidity that includes interference with usual daily activities and impairment of sleep quality. This guidance prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI) is for the management of AR in patients that have failed to achieve adequate relief of symptoms despite treatment with intranasal corticosteroids and/or antihistamines. The guideline is based on evidence and is for use by both adult physicians and paediatricians practising allergy. During the development of these guidelines, all BSACI members were included in the consultation process using a web-based system. Their comments and suggestions were carefully considered by the SOCC. Where evidence was lacking, consensus was reached by the experts on the committee. Included in this guideline are indications and contraindications for immunotherapy, criteria for patient selection, the evidence for short-and long-term efficacy of subcutaneous and sublingual immunotherapy, and discussion on safety and the different modes of immunotherapy including, pre-seasonal and co-seasonal treatments. There are sections on children, allergen standardization, vaccines used in the United Kingdom, oral allergy syndrome, cost effectiveness of immunotherapy and practical considerations of undertaking immunotherapy including recommendations on who should undertake immunotherapy and dosing schedules. Finally, there is discussion on potential biomarkers of response to immunotherapy, the use of component-resolved diagnostics, novel approaches, alternative routes and potential areas for future research.Keywords aeroallergens, allergen, allergic rhinitis, allergen standardization, allergy to animals, allergy to house dust mites, asthma, BSACI, cat allergy, component-resolved diagnostics, cost effectiveness, dosing schedules, grass pollen, guideline, immunotherapy, oral allergy syndrome, perennial rhinitis, pollinosis, ragweed allergy, SAR, seasonal pollen induced rhinitis, subcutaneous immunotherapy, sublingual immunotherapy, tree pollen Submitted 19 February 2011; revised 6 May 2011; accepted 9 May 2011. Executive summaryUntreated rhinitis represents a major cause of morbidity that includes interference with usual daily activities and impaired sleep quality. Immunotherapy, both subcutaneous and sublingual, is an effective treatment for adults and children with severe allergic rhinitis (AR) that does not respond to conventional pharmacotherapy and allergen avoidance measures. The efficacy of immunotherapy depends on correct patient selection, the type of allergen and the product chosen for treatment. Each vaccine requires individual assessment before recommendation for routine use.

show abstract

Section: Dosing Schedules For Subcutaneous Immunotherapymentioning

confidence: 99%

Immunotherapy for allergic rhinitis

Walker¹,

Durham

Till

et al. 2011

Clin Experimental Allergy

146

125

View full text Add to dashboard Cite

show abstract

“…Therapeutic trials have been conducted in both pediatric and adult patients with allergic rhinitis, allergic conjunctivitis, and asthma to grasses, trees, or ragweed. 12,13 Pollinex Quattro is administered as a preseasonal course of 4 injections over at least 3 weeks annually. Therapy has been shown to significantly reduce skin prick test reactions and the seasonal allergen-induced increase in IgE levels while increasing allergen-specific IgG levels.…”

Section: Toll-like Receptorsmentioning

confidence: 99%

Future forms of immunotherapy

Casale

Stokes

2011

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

“…[15][16][17] Thus, it significantly reduces healthcare cost in terms of repeated administration of injections and it is convenient for the patients.…”

Section: Allergic Rhinitismentioning

confidence: 99%

An update on allergen immunotherapy

Arshad

2016

Clinical Medicine

View full text Add to dashboard Cite

AAllergen-specific immunotherapy (AIT) has been used to treat allergic diseases for over a century. It is the only treatment that addresses immune dysfunction underlying allergic responses rather than simply treating symptoms or suppressing inflammation. Its safety and efficacy in allergic rhinitis, asthma and insect allergy has been documented in a number of systematic reviews but its cost effectiveness is less clear. AIT reduces symptoms and requirement for medication, while improving quality of life. Further, the effect continues for years after discontinuation of treatment. However, evidence regarding cost effectiveness is limited. During AIT, allergen extracts are administered through a subcutaneous or sublingual route for 3-5 years. Subcutaneous immunotherapy is more effective in inducing long-term remission but systemic reactions do occur occasionally. Sublingual immunotherapy is safer and more convenient for the patient but evidence regarding its long-term efficacy is patchy. AIT is used widely in western Europe and the USA. In the UK, subcutaneous immunotherapy is often used for bee and wasp allergy, while both subcutaneous and sublingual immunotherapies are used for severe allergic rhinitis and occasionally for house dust mite and pet allergies. In conclusion, AIT is safe and effective and should be considered as a treatment option for those with allergic diseases.

show abstract

Pollinex Quattro Tree: allergy vaccine

Cited by 23 publications

References 15 publications

Immunotherapy for allergic rhinitis

Immunotherapy for allergic rhinitis

Future forms of immunotherapy

An update on allergen immunotherapy

Contact Info

Product

Resources

About